Oncorus is focused on realizing the full promise of IV-administered, self-amplifying RNA medicines to transform outcomes for cancer patients
Oncorus is focused on realizing the full promise of IV-administered, self-amplifying RNA medicines to transform outcomes for cancer patients. The company develops viral immunotherapies for cancer, employing oncolytic viruses and self-amplifying RNA platforms designed to selectively infect and destroy cancer cells while stimulating the immune system.